Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma

Schagen, Sanne B.; Dam, F.S.A.M. van; Müller, Martin; Boogerd, Willem; Lindeboom, J.; Bruning, P.F.

doi:10.1002/(sici)1097-0142(19990201)85:3<640::aid-cncr14>3.0.co;2-g

Cited by 582 publications

(453 citation statements)

References 33 publications

(11 reference statements)

Supporting

Mentioning

392

Contrasting

Unclassified

Order By: Relevance

“…4,6–8 However, our findings differed in terms of memory performance; specifically, we did not find group differences in verbal and nonverbal memory. This could be the result of several features of our sample.…”

Section: Discussioncontrasting

confidence: 79%

Neuropsychological Outcomes of Older Breast Cancer Survivors: Cognitive Features Ten or More Years After Chemotherapy

Yamada¹,

Denburg²,

Beglinger³

et al. 2010

Journal of Neuropsychiatry

View full text Add to dashboard Cite

The authors examined the long-term cognitive implications of cancer treatment among breast cancer survivors over 65 years old who received treatment during midlife. Thirty women survivors were matched with 30 noncancer, healthy older adults in terms of age, education, and IQ. The cancer survivors scored significantly lower in the cognitive domains of executive functioning, working memory, and divided attention, reflecting potential dysfunction in frontal-subcortical brain regions. Our findings suggest that among breast cancer survivors who remain disease-free for more than a decade, the previous cancer treatment may further augment cognitive dysfunction associated with age-related brain changes.

show abstract

Section: Discussioncontrasting

confidence: 79%

Neuropsychological Outcomes of Older Breast Cancer Survivors: Cognitive Features Ten or More Years After Chemotherapy

Yamada¹,

Denburg²,

Beglinger³

et al. 2010

Journal of Neuropsychiatry

View full text Add to dashboard Cite

show abstract

“…The observation of impaired memory in the present study and the ones by Winocur et al [35] and Reiriz et al [24] is consistent with a growing number of clinical reports of impaired learning and memory after chemotherapy [2,22,26]. However, it is clear that additional studies are needed to fully characterize the effects of chemotherapeutic agents on learning and memory in rat models.…”

supporting

confidence: 92%

Cancer chemotherapy impairs contextual but not cue-specific fear memory

MacLeod

DeLeo²,

Hickey³

et al. 2007

Behavioural Brain Research

View full text Add to dashboard Cite

This study examined the effects of a standard breast cancer chemotherapeutic protocol on learning and memory in rats. Ovariectomized rats were treated once a week for 3 weeks with a combination of cyclophosphamide and doxorubicin prior to training in a classical fear conditioning task. Training took place 1 week after the final treatment. During the training session, an auditory stimulus (a tone) was paired with a mild foot-shock. The resulting conditioned fear to the tone (cue-specific fear) and to the training environment (contextual fear) was measured in subsequent test sessions. Chemotherapy did not affect the acquisition of the conditioned response (freezing) during the training session or the expression of fear during the tone test session. In contrast, rats treated with cyclophosphamide and doxorubicin exhibited decreased freezing during the context test session, suggestive of a specific deficit in hippocampal-related learning and memory. Together, these data indicate that administration of cyclophosphamide and doxorubicin may have toxic effects on the hippocampus and results in specific learning deficits shortly after treatment has ended. KeywordsCyclophosphamide; Doxorubicin; Chemotherapy; Learning; Rat A growing body of evidence indicates that cancer chemotherapy results in cognitive changes during treatment, immediately post-treatment, and up to 10 years following therapy [2,4,15,21,25,32]. The cognitive deficits that are experienced are diverse and vary in severity; however, problems with memory function and executive processes are the most

show abstract

“…Third, older people with cognitive impairment are more frequently isolated (34), and turn away persons who want to help, to avoid facing their difficulties (35). Finally, it is increasingly reported that chemotherapeutic agents can worsen the patient's cognitive status (36)(37)(38). Thus, it is obvious those patients with cognitive impairment at the start of chemotherapy are more vulnerable, and that their vulnerability can be worsened by chemotherapeutic agents (39,40).…”

Section: Discussionmentioning

confidence: 99%

Identification of clinical parameters predictive of one-year survival using two geriatric tools in clinically fit older patients with hematological malignancies: Major impact of cognition

Dubruille

Libert

Roos

et al. 2015

Journal of Geriatric Oncology

View full text Add to dashboard Cite

Little is known about the reliability of G8 screening tool and the prognostic value of clinical parameters within the Comprehensive Geriatric Assessment (CGA) in clinically fit older patients with haematological malignancies. This study was performed to assess the reliability of G8 as a screening tool and to determine the predictive value of CGA items in terms of one-year overall survival (OS). G8 and CGA were proposed to 107 consecutive patients (65-89yrs) with haematological malignancies that were judged clinically fit to receive chemotherapy. Ninety patients were evaluable with both scales; 72% and 80% were defined as "vulnerable" when evaluated with G8 (≤14.5) or CGA (≥2 impairments) respectively. The area under ROC-curve of G8 compared to CGA was 0.749 ± 0.051. Neither G8 nor CGA total score were predictive of one-year OS. However, age (HR=1.09, 95%CI: 1.009-1.185; p=0.029), diagnosis (HR=5.99, 95%CI: 2.322-15.428; p<0.001) and cognitive status (HR=3.50, 95%CI: 1.132-10.849; p=0.030) were predictive of OS. We conclude that in our selected haematological patients 1) the G8 score does not help selecting patients for CGA 2) the G8 and CGA total score do not predict OS 3) in addition to the age and disease itself, cognitive impairment appears to be a powerful prognostic factor.

show abstract

Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma

Cited by 582 publications

References 33 publications

Neuropsychological Outcomes of Older Breast Cancer Survivors: Cognitive Features Ten or More Years After Chemotherapy

Neuropsychological Outcomes of Older Breast Cancer Survivors: Cognitive Features Ten or More Years After Chemotherapy

Cancer chemotherapy impairs contextual but not cue-specific fear memory

Identification of clinical parameters predictive of one-year survival using two geriatric tools in clinically fit older patients with hematological malignancies: Major impact of cognition

Contact Info

Product

Resources

About